tiprankstipranks
KalVista Pharmaceuticals (KALV)
NASDAQ:KALV
US Market
KALV
KalVista Pharmaceuticals
RESEARCH TOOLSreports

KalVista Pharmaceuticals (KALV) Stock News & Sentiment

611 Followers
Ekterly: Strong Global Launch Momentum and Pediatric Upside Support Multi‑Year Growth and $39 Price Target
Premium
Ratings
Ekterly: Strong Global Launch Momentum and Pediatric Upside Support Multi‑Year Growth and $39 Price Target
6d ago
KALV
Sustained EKTERLY Uptake and Shift Toward Oral HAE Therapy Underpin Buy Rating on KalVista
Premium
Ratings
Sustained EKTERLY Uptake and Shift Toward Oral HAE Therapy Underpin Buy Rating on KalVista
18d ago
KALV
Early Outperformance and Expanding On‑Demand HAE Opportunity Justify Buy Rating on KalVista
Premium
Ratings
Early Outperformance and Expanding On‑Demand HAE Opportunity Justify Buy Rating on KalVista
1M ago
KALV
KalVista’s Pediatric HAE Trial for Sebetralstat Reaches Completion, Setting Up a Key Catalyst for KALV
Premium
Company Announcements
KalVista’s Pediatric HAE Trial for Sebetralstat Reaches Completion, Setting Up a Key Catalyst for KALV
3M ago
KALV
Strong Ekterly Launch and Latin America Expansion Underscore Buy Rating on KalVista
Premium
Ratings
Strong Ekterly Launch and Latin America Expansion Underscore Buy Rating on KalVista
3M ago
KALV
KalVista Highlights Strong EKTERLY Launch and Global Uptake
Premium
Company Announcements
KalVista Highlights Strong EKTERLY Launch and Global Uptake
3M ago
8K
KALV
KalVista (Ekterly) Upgraded as 2026 Top Idea: De-Risked Competitive Landscape, Strengthening Launch Trajectory, and Raised $32 Target Support Buy Rating
Premium
Ratings
KalVista (Ekterly) Upgraded as 2026 Top Idea: De-Risked Competitive Landscape, Strengthening Launch Trajectory, and Raised $32 Target Support Buy Rating
3M ago
KALV
More KALV News >

KALV News on the Web

Ekterly: Strong Global Launch Momentum and Pediatric Upside Support Multi‑Year Growth and $39 Price Target
TipRanks News
Neutral
KalVista announces interim Phase 3 data from KONFIDENT-KID trial of EKTERLY
TipRanks News
Neutral
KalVista Pharmaceuticals (KALV) Gets a Buy from Stifel Nicolaus
TipRanks News
Bearish
Major KalVista Stakeholder Makes Eye-Catching Move With Fresh Stock Sale
TipRanks News
Neutral
Sustained EKTERLY Uptake and Shift Toward Oral HAE Therapy Underpin Buy Rating on KalVista
TipRanks News
Bullish
Analysts Offer Insights on Healthcare Companies: Beam Therapeutics (BEAM), KalVista Pharmaceuticals (KALV) and Ionis Pharmaceuticals (IONS)
TipRanks News
Bullish
KalVista price target lowered to $28 from $29 at Citizens
TipRanks News
Bullish
KalVista price target raised to $42 from $39 at Stifel
TipRanks News
Bullish

News Score - Last 7 Days

Not enough data to generate a sentiment score
Media Buzz
This Week0 articles
Weekly Average0 articles
News Sentiment
Currently, no data available
See how Bullish or Bearish a stock is based on its recent media coverage.

This score is generated using a formula that combines Media Buzz and News Sentiment.

Media Coverage Analysis

The historical news coverage of this asset in the last three months.

FAQ

What is KALV’s Media Buzz Sentiment?
Currently, no data Available
What is KALV’s weekly average amount of articles?
Currently, no data Available
What is KALV’s News Sentiment?
Currently, no data Available
Healthcare Stocks that are Trending in the News
AORTArtivion
STAAStaar Surgical
IVVDInvivyd
SLPSimulations Plus
REPLReplimune Group
Showing the stocks with the most bullish news sentiment over the past week